Skip to main content
Signal8
Launch Terminal

BIO-PATH HOLDINGS, INC. (BPTH)

Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Bio-Path Holdings, Inc. logo

Bio-Path Holdings, Inc.

OTC:BPTHHealthcare
$0.0003
Mkt Cap$15K
Float50.28M
O/S50.3M
Vol
$ Vol
RVOL
Inst Own-
SI<0.1%
Earnings
Dilution
Bio-Path Holdings, Inc. logoOTC:BPTH$0.0003
Phase Distribution
6 lead-sponsored trials·4 active·1 completed
Phase 14
Phase 1/21
Phase 21
Status Overview
Recruiting3
Active, not recruiting1
Completed1
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 2
    Recruiting

    Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

    BP1001 in combination with Ventoclax plus decitabine, BP1001 plus decitabine

    Acute Myeloid Leukemia (AML)

    Enrollment
    108
    Start
    May 2016
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2028est.
    NCT02781883
  • Phase 1/2
    Withdrawn

    Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

    BP1001 (varying dose), BP1001 (fixed dose)

    Chronic Myelogenous Leukemia, Ph1-Positive, Acute Myeloid Leukemia +1

    Enrollment
    0
    Start
    Sep 2017
    Primary Completion
    May 2020
    Completion
    May 2020
    NCT02923986
  • Phase 1
    Completed

    Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

    BP1001, BP1001 in combination with LDAC

    Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia +2

    Enrollment
    60
    Start
    Jun 2010
    Primary Completion
    Mar 2017
    Completion
    Mar 2017
    NCT01159028
  • Phase 1
    Active, not recruiting

    A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

    L-Bcl-2 antisense oligonucleotide

    Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL) +8

    Enrollment
    30
    Start
    Nov 2020
    Primary Completion
    Apr 2025est.
    Completion
    Apr 2025est.
    NCT04072458
  • Phase 1
    Recruiting

    BP1001-A in Patients With Advanced or Recurrent Solid Tumors

    BP1001-A (Liposomal Grb2 Antisense Oligonucleotide), BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel

    Solid Tumor, Adult, Carcinoma, Ovarian Epithelial +4

    Enrollment
    50
    Start
    Aug 2022
    Primary Completion
    Jul 2027est.
    Completion
    Oct 2027est.
    NCT04196257
  • Phase 1
    Recruiting

    A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

    BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide, Decitabine (in combination with BP1002)

    Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

    Enrollment
    48
    Start
    Aug 2022
    Primary Completion
    Mar 2027est.
    Completion
    Sep 2027est.
    NCT05190471
Search ClinicalTrials.gov for “Bio-Path Holdings”